OverviewSuggest Edit

ASIT Biotech is a clinical-stage biopharmaceutical company, which focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies. The Comany's products include gp-ASIT+ for the treatment of grass pollen allergy administered by subcutaneous injections; hdm-ASIT+ for the treatment of house dust mite allergy administered by subcutaneous injections; and food-ASIT+ for the treatment of peanut, cow's milk, and egg white allergies.

TypePublic
Founded1997
HQLiège, BE
Websiteasitbiotech.com

Latest Updates

Employees (est.) (Feb 2019)26(+30%)
Share Price (Nov 2020)€0.2 (-2%)
Cybersecurity ratingAMore

Key People/Management at ASIT Biotech

Michel Baijot

Michel Baijot

Director & CEO
Yves Désiront

Yves Désiront

Chairman of the Board
François Meurgey

François Meurgey

Director
Frank Hazevoets

Frank Hazevoets

CFO
Beatrice de Vos

Beatrice de Vos

CMO
Philippe Degeer

Philippe Degeer

Director
Show more

ASIT Biotech Office Locations

ASIT Biotech has offices in Liège and Sint-Lambrechts-Woluwe
Liège, BE (HQ)
Rue des Chasseurs Ardennais 7
Sint-Lambrechts-Woluwe, BE
Arianelaan 5
Show all (2)

ASIT Biotech Financials and Metrics

ASIT Biotech Revenue

Market capitalization (19-Nov-2020)

3.9m

Closing stock price (19-Nov-2020)

0.2
ASIT Biotech's current market capitalization is €3.9 m.
Show all financial metrics

ASIT Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

ASIT Biotech Online and Social Media Presence

Embed Graph

ASIT Biotech News and Updates

ASIT Biotech Continues its Transformation From Research to Late Stage Clinical Development

BRUSSELS, Belgium, July 01, 2019 (GLOBE NEWSWIRE) -- ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, announces that shareholders h…

ASIT Biotech Blogs

ASIT biotech signs a preliminary partnership agreement and requests an extension of his suspension of 2 months

ASIT biotech signs a preliminary partnership agreement and requests an extension of his suspension of 2 months

Declaration of dissociation of a member of the Board of Directors at the General Assembly

Declaration of dissociation of a member of the Board of Directors at the General Assembly

ASIT biotech mode of action study of gp-ASIT+™ for grass pollen allergy published in The Journal of Allergy and Clinical Immunology (JACI)

ASIT biotech mode of action study of gp-ASIT+™ for grass pollen allergy published in The Journal of Allergy and Clinical Immunology (JACI)

ASIT biotech receives GMP certification for its manufacturing site in Liège, Belgium

ASIT biotech receives GMP certification for its manufacturing site in Liège, Belgium

ASIT biotech firmly on course for readout of Phase III clinical study in grass pollen allergy

ASIT biotech firmly on course for readout of Phase III clinical study in grass pollen allergy

ASIT biotech presents its 2019 half year results and provides further update on its clinical programs until end-2019

ASIT biotech presents its 2019 half year results and provides further update on its clinical programs until end-2019
Show more

ASIT Biotech Frequently Asked Questions

  • When was ASIT Biotech founded?

    ASIT Biotech was founded in 1997.

  • Who are ASIT Biotech key executives?

    ASIT Biotech's key executives are Michel Baijot, Yves Désiront and François Meurgey.

  • How many employees does ASIT Biotech have?

    ASIT Biotech has 26 employees.

  • Who are ASIT Biotech competitors?

    Competitors of ASIT Biotech include Creative Biolabs, KiOmed Pharma and Hoth Therapeutics.

  • Where is ASIT Biotech headquarters?

    ASIT Biotech headquarters is located at Rue des Chasseurs Ardennais 7, Liège.

  • Where are ASIT Biotech offices?

    ASIT Biotech has offices in Liège and Sint-Lambrechts-Woluwe.

  • How many offices does ASIT Biotech have?

    ASIT Biotech has 2 offices.